capecitabine has been researched along with Benign Neoplasms in 235 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (5.11) | 18.2507 |
| 2000's | 82 (34.89) | 29.6817 |
| 2010's | 101 (42.98) | 24.3611 |
| 2020's | 40 (17.02) | 2.80 |
| Authors | Studies |
|---|---|
| Bijl, I; Bins, S; de Bruijn, P; de Man, FM; Eskens, FALM; Heersche, N; Mathijssen, RHJ; Oomen-de Hoop, E; van der Gaast, A; van Doorn, L | 1 |
| Abad-Santos, F; Borobia, AM; Colomer, R; García-Alfonso, P; García-García, I; García-González, X; Herrero, MJ; López-Fernández, LA; Mondéjar, R; Páez, D; Safont, MJ; Saiz-Rodríguez, M; Salazar, J | 1 |
| Amarantidis, K; Balgkouranidou, I; Biziota, E; Ioannou, C; Kakolyris, S; Koukaki, T; Manolopoulos, VG; Ragia, G; Xenidis, N | 1 |
| Clasen, SC; Lefebvre, B; Turk, A; Vater, LB | 1 |
| Franco, PIG; Li, RK; Pandy, JGP | 1 |
| Cai, Q; Guo, L; Liu, J; Shangguan, C; Shi, M; Shi, Y; Wu, J; Xi, W; Yang, H; Zhang, J; Zhou, C | 1 |
| Ålgars, A; Bärlund, M; Flygare, P; Frödin, JE; Glimelius, B; Hagman, H; Halonen, P; Heervä, E; Kallio, R; Kinos, S; Kwakman, JJM; Liposits, G; McDermott, R; O'Reilly, M; Osterlund, P; Pfeiffer, P; Punt, CJA; Ristamäki, R; Röckert, R; Salminen, T; Shah, CH; Sorbye, H; Soveri, LM; Teske, AJ; van Werkhoven, E | 1 |
| Carriat, L; Ciccolini, J; Quaranta, S; Rony, M; Solas, C | 1 |
| Amano, J; Azuma, Y; Endo, M; Fujii, E; Ishiguro, T; Kayukawa, Y; Kinoshita, Y; Kitazawa, T; Maruyama, T; Miyazaki, Y; Nishito, Y; Sakamoto, Y; Sano, Y; Sato, Y; Shinozuka, J; Tanaka, T; Teramoto-Seida, C; Tsunenari, T; Yoshida, A | 1 |
| Chun, JW; Douangprachanh, S; Han, N; Han, SS; Jang, HY; Joo, HJ; Kim, TH; Koh, YH; Lee, WJ; Park, HM; Park, SJ; Woo, SM | 1 |
| Rubin, R | 1 |
| Burgos, V; González-Chavarría, I; Iturra-Beiza, H; Paz, C; Ulrich, H; Villegas, C | 1 |
| Chai, S; Hamilton, A; Hanson, SL; Hwang, JJ; Kadakia, KC; Larck, C; Lopes, KE; Moore, DC; Morris, SA; Musselwhite, LW; Patel, JN; Smith, M; Steuerwald, N; Swift, K | 1 |
| Hu, H; Wang, Y; Yu, L; Zeng, S | 1 |
| Baars, A; Beijnen, JH; Cats, A; Creemers, GJ; de Man, FM; Droogendijk, HJ; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Imholz, ALT; Knikman, JE; Lopez-Yurda, M; Lunenburg, CATC; Mandigers, CMPW; Mathijssen, RHJ; Meulendijks, D; Nieboer, P; Portielje, JEA; Schellens, JHM; Swen, JJ; Valkenburg-van Iersel, L; van der Poel, MHW; Vulink, A; Wilting, TA | 1 |
| Kang, S; Kim, B; Kim, MS; Yeon, B; Yoo, M; Yu, YM | 1 |
| Azevedo, PG; Bastos-Rodrigues, L; Bicalho, MA; Coelho, LG; Cunha-Junior, GF; De Marco, L; Magno, LAV | 1 |
| Beijnen, JH; Cats, A; de Vries, N; Deenen, MJ; Huitema, ADR; Jacobs, BAW; Joerger, M; Meulendijks, D; Rosing, H; Schellens, JHM | 1 |
| Chevrier, R; Chollet, P; Devaud, H; Dubray-Longeras, P; Durando, X; Kwiatkowski, F; Mouret-Reynier, MA; Poirier, C; Thivat, E; Vacher, L; van Praagh-Doreau, I | 1 |
| Li, G; Ma, B; Wang, Y; Xu, H; Zhuang, W | 1 |
| Aebi, S; Amstutz, U; Froehlich, TK; García-González, X; Hamzic, S; Joerger, M; Kummer, D; Largiadèr, CR; López-Fernández, LA; Meulendijks, D; Palles, C; Schellens, JHM; Thomlinson, I | 1 |
| Feliu, J; Ghanem, I; Higuera, O; Perez-Wert, P; Rodriguez-Salas, N; Viñal, D | 1 |
| Edeline, J; Frenel, JS; Gilabert, M; Raoul, JL; Senellart, H | 1 |
| Ciccolini, J; De Victor, B; Hilaire, V; Krache, A; Lacarelle, B; Lucas, M; Marin, C; Palmaro, C; Quaranta, S; Solas, C; Ugdonne, R | 1 |
| Beijnen, JH; de Vries, N; Huitema, ADR; Jacobs, BAW; Marchetti, S; Nuijen, B; Pluim, D; Roosendaal, J; Rosing, H; Schellens, JHM; van Werkhoven, E | 1 |
| Barranger, E; Bozec, A; Cassuto, O; Chamorey, E; Etienne, MC; Ferrero, JM; Francois, E; Largillier, R; Milano, G; Peyrade, F; Schiappa, R; Viotti, J | 1 |
| Hsieh, HN; Lu, HY | 1 |
| Alba, E; Benítez, J; Caronia, D; Cuadrado, A; de la Torre-Montero, JC; García-Saenz, JA; González-Neira, A; Kojic, A; López-Fernández, LA; Losada, A; Lozano, M; Martín, M; Milne, RL; Moreno, LT; Nuñez-Torres, R; Pérez-Moreno, M; Pita, G; Ribelles, N; Ruiz-Pinto, S; Shahbazi, MN | 1 |
| Jaehde, U; Ko, YD; Krolop, L; Ringsdorf, S; Schmulenson, E; Simons, S | 1 |
| Fujiwara, K; Goto, K; Harada, T; Hayashi, T; Kaneda, H; Kenmotsu, H; Kimura, M; Kogure, Y; Koike, T; Matsui, R; Nishio, M; Nogami, N; Seto, T; Shimizu, S; Shimokawa, M; Suzuki, K; Takiguchi, T | 1 |
| Arnold, D; Blohmer, JU; Bokemeyer, C; Borner, M; Brucker, S; Burmeister, T; Cascorbi, I; de Wit, M; Decker, T; Dietz, A; Einsele, H; Eisterer, W; Folprecht, G; Hilbe, W; Hoffmann, J; Hofheinz, RD; Knauf, W; Köhne, CH; Kunzmann, V; Largiadèr, CR; Lorenzen, S; Lüftner, D; Moehler, M; Nöthen, MM; Pox, C; Reinacher-Schick, A; Scharl, A; Schlegelberger, B; Schwab, M; Seufferlein, T; Sinn, M; Stroth, M; Tamm, I; Trümper, L; Wilhelm, M; Wöll, E; Wörmann, B | 1 |
| Astras, G; Charalambous, A; Filippou, E; Paikousis, L; Tsitsi, T | 1 |
| Koutsilieri, S; Patrinos, GP | 1 |
| Galettis, P; Martin, JH; Schneider, JJ | 1 |
| Fang, F; Henry, NL; Hertz, DL; Kidwell, KM; Koo, K; Kwon, JW; Pasternak, AL; Sahai, V; Shakeel, F | 1 |
| Beijnen, JH; Derissen, EJB; Dorlo, TPC; Huitema, ADR; Jacobs, BAW; Janssen, JM; Marchetti, S; Roosendaal, J | 1 |
| Choi, YH; Keller, D; Kim, RB; Legan, RM; Lenehan, J; Mailloux, J; Medwid, S; Nevison, S; Panuganty, V; Povitz, BL; Sarma, S; Schwarz, UI; Siebring, V; Teft, WA; Welch, S; Wigle, TJ; Winquist, E | 1 |
| Diasio, RB; King, DA; Saif, MW | 1 |
| Chen, L; Chou, C; Li, C; Ngorsuraches, S; Qian, J | 1 |
| Abdelmaseih, R; Abdelmasih, R; Balaraman, R; Blanco, A; Desai, K; Patel, J; Pothen, J | 1 |
| Beijnen, JH; Dorlo, TPC; Huitema, ADR; Jacobs, BAW; Kurk, SA; May, AM; Molenaar-Kuijsten, L; Steeghs, N | 1 |
| Karthikeyan, K; Madhu, CS; Sameera, KV; Shaji, S; Swetha, MAC | 1 |
| Aliev, A; Beijnen, JH; Cats, A; de Boer, A; de Vries, N; Deenen, MJ; Henricks, LM; Jacobs, BAW; Mandigers, CMPW; Meulendijks, D; Rosing, H; Schellens, JHM; Soesan, M; van Werkhoven, E | 1 |
| Chay, WY; Chia, JWK; Choo, SP; Dent, RA; Koh, KX; Koo, WH; Kwok, LL; Lo, SK; Loh, M; Mok, ZY; Ng, RCH; Soong, RCT; Syn, N; Tan, S; Tham, CK; Toh, HC; Wong, NS; Yap, YS | 1 |
| Ozaki, A | 1 |
| Cubiró, X; Garcia-Muret, MP; Planas-Ciudad, S; Puig, L | 1 |
| Beaumont, H; Dittlot, C; Falewee, MN; Hebert, C; Iannessi, A | 1 |
| Barin-Le-Guellec, C; Becquemont, L; Bobin-Dubigeon, C; Boyer, JC; Broly, F; Ciccolini, J; Etienne-Grimaldi, MC; Evrard, A; Fonrose, X; Harle, A; Hennart, B; Lafay-Chebassier, C; Loriot, MA; Masskouri, F; Milano, G; Narjoz, C; Paci, A; Picard, N; Poinsignon, V; Quaranta, S; Royer, B; Schmitt, A; Thomas, F; Verstuyft, C; Wozny, AS | 1 |
| Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D | 1 |
| Chen, G; Dong, C; Li, W; Peng, J; Qiu, M; Wang, C; Wang, F; Wu, Q; Yu, H; Yuan, Y; Zhang, J; Zhang, M; Zhao, Q; Zhou, W; Zhu, B | 1 |
| Park, JY | 1 |
| Dolan, ME; Dudek, SM; Kim, D; Li, R; Ritchie, MD; Wheeler, HE | 1 |
| Charles, BG; Cowley, D; Duley, JA; George, R; Harris, M; Helsby, N; Ni, M; Norris, RL; Shannon, C; Sheffield, L; van Kuilenburg, ABP | 1 |
| Fuss, H; Jung, S; Lademann, J | 1 |
| Beijnen, JH; Jacobs, BAW; Pluim, D; Schellens, JHM; Tzani, A; van der Laan, P | 1 |
| Baars, A; Beijnen, JH; Cats, A; Creemers, GJ; de Man, FM; Dezentjé, VO; Droogendijk, HJ; Frederix, GWJ; Gelderblom, H; Guchelaar, HJ; Hamberg, P; Henricks, LM; Imholz, ALT; Jansen, RLH; Jeurissen, FJF; Kienhuis, E; Koopman, M; Lunenburg, CATC; Mandigers, CMPW; Mathijssen, RHJ; Meulendijks, D; Nieboer, P; Portielje, JEA; Rosing, H; Schellens, JHM; Swen, JJ; Ten Tije, AJ; van de Poel, MHW; van Kuilenburg, ABP; van Schaik, RHN; Werkhoven, EV | 1 |
| Brell, JM; Carver, JR; Denlinger, CS; Dimond, EP; Kircher, SM; Ky, B; O'Neill, A; Upshaw, JN; Wagner, LI | 1 |
| Cecchin, E; Dreussi, E; Fiocco, M; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Lunenburg, CATC; Meulendijks, D; Peters, FP; Schellens, JHM; Swen, JJ; Toffoli, G | 1 |
| Adjei, AA; Boland, P; Brady, W; Dy, GK; Fetterly, G; Iyer, R; LeVea, C; Ma, WW; Mantione, K; Pitzonka, L; Schihl, S; Straubinger, RM; Tan, W; Whitworth, A; Wilton, J; Xie, H | 1 |
| Brutcher, E; Christensen, D; Hennessey Smith, M; Koutlas, JB; Sellers, JB; Thompson, J; Timmons, T | 1 |
| Beijnen, JH; Cats, A; de Boer, A; Deenen, MJ; Henricks, LM; Meulendijks, D; Schellens, JHM; van Merendonk, LN | 1 |
| Baars, A; Beijnen, JH; Cats, A; Creemers, GJ; de Man, FM; Dezentjé, VO; Droogendijk, HJ; Frederix, GWJ; Gelderblom, H; Guchelaar, HJ; Hamberg, P; Henricks, LM; Imholz, ALT; Jansen, RLH; Jeurissen, FJF; Kienhuis, E; Koopman, M; Lunenburg, CATC; Mandigers, CMPW; Mathijssen, RHJ; Meulendijks, D; Nieboer, P; Portielje, JEA; Rosing, H; Schellens, JHM; Swen, JJ; Ten Tije, AJ; van de Poel, MHW; van Kuilenburg, ABP; van Schaik, RHN; van Werkhoven, E | 1 |
| Bakema, R; Brinkman, I; Kleinjan, JP; van Rooijen, JM; van Zanden, JJ | 1 |
| Lam, CW; Lam, KO; Lee, VHF; Luk, MY; Tong, CC | 1 |
| Cats, A; Guchelaar, HJ; Henricks, LM; Lunenburg, CATC; Mathijssen, RHJ; Schellens, JHM | 1 |
| Arnold, S; Durbin, EB; Kolesar, J; Miller, R; Nichols, D; Weiss, HL; Wu, J | 1 |
| Amylidi, AL; Angelaki, A; Aravantinos, G; Boumpoucheropoulos, S; Fildissis, G; Lampropoulou, DI; Laschos, K; Nanou, E; Nasioulas, G; Papadopoulou, E; Soupos, N; Zidianakis, V | 1 |
| Dołegowska, B; Ostapowicz, A | 1 |
| Boxberger, F; Dörje, F; Harich, HD; Hohenberger, W; Koch, S; Neurath, MF; Siebler, J; Wein, A | 1 |
| Bhuva, N; Buckley, A; Harrison, M; Kelly, C; Saunders, M | 1 |
| Bilic, S; Burris, HA; de Vries, EG; Gietema, JA; Goldbrunner, M; Infante, JR; Oldenhuis, CN; Parker, K; Scott, JW; Sharma, S; Yang, L | 1 |
| Seaman, SR; Wason, JM | 1 |
| Baracos, VE; Maia, YL; Ormsbee, M; Prado, CM; Sawyer, MB | 1 |
| Ait-Tihyaty, M; Jean-Claude, BJ; Larroque-Lombard, AL; Rachid, Z | 1 |
| Ames, MM; Erlichman, C; Goetz, MP; Goldberg, RM; Grothey, AA; Kuffel, MA; Mandrekar, SJ; McGovern, RM; McKean, HA; McWilliams, R; Reid, JM; Safgren, SL; Tan, AD | 1 |
| Fujii, C; Fujino, M; Fukunaga, M; Hachino, Y; Hamaguchi, Y; Imamura, H; Iseki, C; Ishizaka, T; Kamigaki, S; Kawabata, R; Kawase, T; Kimura, Y; Yamamoto, E | 1 |
| Arrowood, CC; Bendell, JC; Brady, JC; Broderick, S; Cushman, SM; Dellinger, A; Hsu, SD; Hurwitz, HI; Kozloff, MF; Meadows, J; Meadows, KL; Morse, MA; Murphy, J; Nixon, AB; Pang, H; Rangwala, F; Starodub, AN; Starr, A; Strickler, JH; Tourt-Uhlig, S; Uronis, HE; Wallace, J; Zafar, SY | 1 |
| Astsaturov, I; Ball, DS; Cade, DN; Cohen, SJ; Dickens, A; Konski, AA; Marlow, C; Meropol, NJ; Meyer, JE; Putnam, S; Yu, JQ | 1 |
| Alhamed, A; Chatterjee, A; Foster, DA; Hosny, C; Mukhopadhyay, S; Saqcena, M | 1 |
| Chen, J; Chen, X; Dai, C; Wu, X; Yu, B; Zhao, C; Zhou, C | 1 |
| Bardy-Bouxin, N; Calles, A; Calvo, E; Campone, M; Duvillié, L; Isakoff, SJ; Leip, E; Turnbull, K; Wang, D | 1 |
| Carmichael, L; Deming, DA; Eickhoff, J; Holen, KD; Ivy, P; Kolesar, J; Leverence, R; Liu, G; LoConte, NK; Lubner, SJ; Mulkerin, DL; Razak, AR; Schelman, WR; Siu, L; Tevaarwerk, A | 1 |
| Arrowood, CA; Honeycutt, W; Howard, L; Hurwitz, HI; Latta, K; Meadows, KL; Niedzwiecki, D; Rushing, C | 1 |
| Hassan, NB; Norazwany, Y; Norhayati, I; Norsa'adah, B; Roslan, MH; Wan Nazuha, WR; Zahrina, AK | 1 |
| Magdy, T; Nies, AT; Schwab, M; Zanger, UM | 1 |
| Adjei, AA; Bendell, J; Benhadji, KA; Callies, S; Dy, GK; Fetterly, G; Infante, JR; Ma, WW | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Chen, X; Dai, X; Deng, P; Ding, L; Ji, C; Zhong, D | 1 |
| Bekaii-Saab, T; Kleiber, B; Lustberg, MB; Mikhail, S; Monk, P; Mortazavi, A; Ruppert, AS; Villalona-Calero, M | 1 |
| Bendell, JC; Earwood, C; Hart, L; Infante, JR; Jones, SF; Lane, CM; Moyhuddin, A; Murphy, P; Pant, S; Patton, J; Penley, WC; Thompson, D | 1 |
| Amstutz, U; Beijnen, JH; Cats, A; Deenen, MJ; Froehlich, TK; Gross, E; Henricks, LM; Jennings, BA; Kleibl, Z; Kleiblova, P; Koopman, M; Largiadèr, CR; Marinaki, AM; Meulendijks, D; Palles, C; Punt, CJ; Sanderson, JD; Schellens, JH; Schwab, M; Sonke, GS; Tomlinson, I; van Kuilenburg, AB; Zanger, UM | 1 |
| Beijnen, JH; Derissen, EJ; Huitema, AD; Jacobs, BA; Rosing, H; Schellens, JH | 1 |
| Beijnen, JH; de Vries, N; Huitema, AD; Jacobs, BA; Marchetti, S; Meulenaar, J; Nuijen, B; Pluim, D; Rosing, H; Schellens, JH; Tibben, MM | 1 |
| Florek, S; Fuss, H; Huang, MD; Jung, S; Lademann, J; Meinke, MC; Patzelt, A | 1 |
| Amadori, D; Bianchini, E; Casadei Gardini, A; Frassineti, GL; Gallani, ML; Masini, C; Maugeri, A; Menozzi, S; Minguzzi, M; Nanni, O; Palazzini, S; Restuccia, S; Scarpi, E; Tenti, E; Valgiusti, M | 1 |
| Gelderblom, H; Guchelaar, HJ; Lunenburg, CA; Swen, JJ; van Staveren, MC | 1 |
| Hara, S; Miwa, Y; Naito, M; Shimamoto, C; Yamamoto, T | 1 |
| Bai, G; Beaver, JA; Charlab, R; Chen, XH; Cheng, J; Dinin, J; Dorff, SE; Ibrahim, A; Ison, G; Jin, R; Kim, G; Liu, Q; Marathe, A; McGuinn, WD; McKee, AE; Palmby, TR; Pazdur, R; Pierce, W; Sridhara, R; Stephens, O; Tang, S; Wang, Y; Ysern, X | 1 |
| Aliev, A; Beijnen, JH; Cats, A; de Graaf, H; Henricks, LM; Jacobs, BA; Meijer, J; Meulendijks, D; Rozeman, L; Schellens, JH; van Kuilenburg, AB | 1 |
| Boven, E; Guchelaar, HJ; Lam, SW | 1 |
| Bamat, MK; Cartwright, TH; El-Rayes, BF; Fakih, MG; King, TR; Ma, WW; Posey, JA; Saif, MW; von Borstel, RW | 1 |
| Collins, JM; Douglas, KA; Jones, SK; Lawhorn-Crews, JM; Mangner, TJ; McHugh, CI; Modi, D; Shields, AF | 1 |
| de Haan, N; de Lemos, ML; Kovacic, L; Schaff, K; Walisser, S | 1 |
| Dezentjé, V; Dobritzsch, D; Hennekam, RC; Hertz, JM; Jansen, RL; Knegt, LC; Los, M; Maurer, D; Meijer, J; Meinsma, R; van Huis-Tanja, LH; van Kampen, RJ; van Kuilenburg, AB; Zoetekouw, L | 1 |
| Baars, A; Boot, H; Kwakman, JJM; Pfeiffer, P; Pruijt, JFM; Punt, CJA; Winther, SB | 1 |
| Aebi, S; Amstutz, U; Hamzic, S; Joerger, M; Kummer, D; Largiader, CR; Milesi, S; Mueller, D | 1 |
| Crespo-Diz, C; Fernández-Ribeiro, F; Olivera-Fernández, R | 1 |
| Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW | 1 |
| Eberhardt, S; Lee, F; Lee, SJ; Lu, H; Maestas, A; Rabinowitz, I; Royce, M; Sayar, H; Shen, Z; Smith, H; Verschraegen, C | 1 |
| Koukourakis, GV; Koukourakis, MJ; Kouloulias, V; Kouvaris, J; Zabatis, H; Zacharias, GA | 1 |
| Alberti, DB; Attia, S; Bailey, HH; Campbell, TC; Cleary, JF; Eickhoff, JC; Holen, KD; Huie, MS; Liu, G; McFarland, TA; Morgan-Meadows, S; Mulkerin, DL; Schelman, WR; Tevaarwerk, AJ; Traynor, AM; Wilding, G | 1 |
| Kerr, DJ; Midgley, R | 1 |
| Borg, C; Chaigneau, L; Demarchi, M; Fagnoni-Legat, C; Kantelip, JP; Maurina, T; Montange, D; Nguyen, T; Pivot, X; Royer, B; Villanueva, C | 1 |
| Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N | 1 |
| Alberti, D; Eickhoff, J; Feierabend, C; Holen, KD; Kolesar, J; LoConte, NK; Marnocha, R; Mulkerin, D; Oliver, K; Thomas, JP; Wilding, G | 1 |
| Chow, WA; Doroshow, JH; Frankel, P; Gandara, DR; Lenz, HJ; Leong, LA; Lim, D; Margolin, KA; Morgan, RJ; Newman, EM; Shibata, SI; Somlo, G; Synold, TW; Yen, Y | 1 |
| Aebi, S; Amstutz, U; Farese, S; Largiadèr, CR | 1 |
| Balducci, M; D'Agostino, GR; Dinapoli, N; Mantini, G; Massaccesi, M; Mattiucci, GC; Meduri, B; Micciché, F; Nardone, L; Salvi, G; Valentini, V | 1 |
| Arenas-Hernandez, M; Fairbanks, L; Loganayagam, A; Marinaki, AM; Ross, P; Sanderson, JD | 1 |
| Amarantidis, K; Chatzaki, E; Chelis, L; Chiotis, A; Kakolyris, S; Karakitsos, P; Kortsaris, A; Polychronidis, A; Tentes, A; Xenidis, N | 1 |
| Brendel, E; Laferriere, N; Langenberg, MH; Mergui-Roelvink, M; Roodhart, JM; Schellens, JH; van der Sar, J; Verheul, HM; Voest, EE; Witteveen, PO | 1 |
| Emiliani, A; Losanno, T; Manna, G; Seminara, P | 1 |
| Blobe, GC; Dugan, E; Favaro, J; Fernando, NH; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Petros, WP; Truax, R | 1 |
| Marshall, JL; Mikhail, SE; Sun, JF | 1 |
| Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF | 1 |
| Cannistra, SA; Disis, ML; Verweij, J | 1 |
| Albanell, J; Berk, L; Capri, G; Cerny, T; Corradino, I; Cresta, S; Gianni, L; Haluska, F; Hess, D; Locatelli, A; Marsoni, S; Maur, M; Perotti, A; Rivera, VM; Rojo, F; Sessa, C; Viganò, L | 1 |
| Benner, RJ; Benson, AB; Berlin, JD; Denis, LJ; Goff, LW; LoRusso, PM; Rothenberg, ML; Tan, AR; Yin, D | 1 |
| Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL | 1 |
| Bauer, J; Boehm, S; Droege, C; Gallerani, E; Herrmann, R; Hess, D; Jeckelmann, S; Marsoni, S; Miani, M; Sessa, C; Sperka, S | 1 |
| Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N | 1 |
| Beeram, M; Patnaik, A; Saif, MW; Sarantopoulos, J; Takimoto, C; Tolcher, AW | 1 |
| Bendell, JC; Burris, HA; Greco, FA; Hainsworth, JD; Infante, JR; Jones, SF; Lane, CM; Spigel, DR; Yardley, DA | 1 |
| Bartal, A; Liszkay, G; Mátrai, Z; Szûcs, A | 1 |
| Bugnon, O; Jeanneret, LA; Lüthi, F; Schneider, MP; Troxler, S | 1 |
| Beijnen, JH; Deenen, MJ; Klümpen, HJ; Richel, DJ; Schellens, JH; Sparidans, RW; Weterman, MJ; Wilmink, JW | 1 |
| Basche, M; Cleere, D; Eckhardt, SG; Elsayed, YA; Eppers, S; Gore, L; Grolnic, S; Li, J; Moulder-Thompson, SL; O'Bryant, C; Rivera, E | 1 |
| Chan, AK; Choo, BA; Glaholm, J | 1 |
| Cao, D; Flynn, S; Gach, M; Kim, B; McCabe, J; Pizzorno, G; Wan, L; Yan, R; Ziemba, A | 1 |
| Beckeringh, JJ; Boven, E; Hugtenburg, JG; Timmers, L; van Herk-Sukel, MP | 1 |
| Ellidokuz, H; Eren, M; Koca, D; Oztop, I; Salman, T; Unek, IT; Yilmaz, U | 1 |
| Assenat, E; Bleuse, JP; Mazard, T; Pinguet, F; Portales, F; Poujol, S; Samalin, E; Thezenas, S; Thirion, A; Ychou, M | 1 |
| Farmer, A; Larsen, ME; Tarassenko, L; Weaver, A; Young, A | 1 |
| Bunnell, CA; Fornier, MN; Hortobagyi, GN; Martín, M; Mukhopadhyay, P; Peck, RA; Perez, EA; Roché, HH; Sparano, JA; Thomas, ES; Vahdat, LT; Yelle, L | 1 |
| Flombaum, C; Jhaveri, KD; Latcha, S; Shah, M | 1 |
| Azzariti, A; Basile, A; Paradiso, A; Ranieri, G; Ribatti, D; Vacca, A | 1 |
| Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M | 1 |
| Hirashima, Y; Shirao, K | 1 |
| Beijnen, JH; Cats, A; Deenen, MJ; Mandigers, CM; Schellens, JH; Soesan, M; Terpstra, WE | 1 |
| Harada, N; Kurasawa, M; Mori, K; Sato, Y; Yanagisawa, M; Yasuno, H | 1 |
| Huang, RS; Peng, Y; Weng, L; Zhang, L | 1 |
| Malet-Martino, M; Martino, R | 1 |
| Bharara, S; Blanquicett, C; Buchsbaum, DJ; Diasio, RB; Gillespie, GY; Johnson, MR; Miller, CR; Nabors, LB | 1 |
| Clark, JW; Fuchs, CS; Garcia-Carbonero, R; Michaelson, MD; Paul Eder, J; Ryan, DP; Supko, JG | 1 |
| Kornek, GV; Locker, GJ; Mader, RM; Pluschnig, U; Scheithauer, W; Steger, GG; Wenzel, C | 1 |
| Blesch, KS; Burger, HU; Gieschke, R; Reigner, BG; Steimer, JL; Tsukamoto, Y | 1 |
| Orel, NF | 1 |
| Davis, ID; Green, M; Jefford, M; McClure, B; Michael, M; Rosenthal, MA; Smith, J; Waite, B; Zalcberg, J | 1 |
| Mosley, ST; Rich, TA; Shepard, RC | 1 |
| Agelaki, S; Amarantidis, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Xenidis, N | 1 |
| Ferrero, JM; François, E; Milano, G | 1 |
| Rustum, YM | 1 |
| Janisch, L; Kimmel, KA; Kindler, HL; Macek, TA; Olson, SC; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ | 1 |
| Lokich, J | 1 |
| Fei, X; Hutchins, GD; Miller, KD; Sledge, GW; Wang, JQ; Zheng, QH | 1 |
| Assadourian, S; deJonge, MJ; Dumez, H; Eskens, FA; Sanderink, GJ; Selleslach, J; Semiond, D; Soepenberg, O; Sparreboom, A; ter Steeg, J; van Oosterom, AT; Verweij, J | 1 |
| Belani, CP; Chatta, GS; Egorin, MJ; Fakih, M; Friedland, DM; Jacobs, SA; Jung, LL; Potter, DM; Ramalingam, S; Ramanathan, RK; Shin, DM; Strychor, S; Tutchko, S; Zamboni, WC | 1 |
| Fukuyama, Y; Koizumi, W; Nomura, N; Ohno, S; Osaki, A; Saeki, T; Satoh, A; Taguchi, T; Takashima, S; Terashima, M; Toge, T; Toi, M | 1 |
| Lindley, C; Walko, CM | 1 |
| Gaffney, EA | 1 |
| Clarke, SJ; Li, KM; Rivory, LP | 1 |
| Abt, M; Camidge, R; Cassidy, J; Grange, S; Jodrell, D; Reigner, B; Weidekamm, E | 1 |
| Creaven, PJ; Fakih, MG; French, RA; Javle, M; Ramnath, N; Repinski, TV; Schwarz, JK; Strychor, S; Trump, D; Zamboni, BA; Zamboni, WC | 1 |
| Adams, N; Barrera, D; Cunningham, C; Graham, S; Nemunaitis, J; Nugent, J; Senzer, N; Stewart, C | 1 |
| Gradishar, WJ | 1 |
| Lokiec, F; Rezaí, K; Urien, S | 1 |
| Amarantidis, K; Chatzaki, E; Kakolyris, S; Karayiannakis, A; Maltezos, E; Romanidis, K; Toromanidou, M; Trichas, M; Tsaroucha, A; Vasiliadis, M | 1 |
| Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B | 1 |
| Hyodo, I | 1 |
| Diasio, R; Ledbetter, L; Saif, MW; Shah, HR | 1 |
| Hildebrand, J | 1 |
| Basche, M; Britten, CD; Carducci, M; Cook, CA; Eckhardt, SG; Green, LJ; Herbst, RS; Jaken, S; Marder, P; Musib, LC; Ray, C; Thornton, D | 1 |
| Shimamura, T; Tada, M; Yamaguchi, K | 1 |
| Cohen, RB; Eckhardt, SG; Gore, L; Gustafson, D; Holden, SN; Mikule, C; Morrow, M; O'Bryant, CL; Palmer, PA; Persky, M; Pierson, AS; Zhang, S | 1 |
| Curtiss, FR | 1 |
| Cognetti, F; Di Segni, S; Fontana, A; Gelibter, AJ; Labianca, R; Lonardi, S; Loupakis, F | 1 |
| Leoni, V; Rocci, L; Santini, D; Tonini, G; Vincenzi, B; Virzí, V | 1 |
| Baker, S; Bulgaru, A; Camacho, F; Chaudhary, I; Desai, K; Einstein, M; Goel, S; Goldberg, G; Gollamudi, R; Karri, S; Kaubisch, A; Mani, S | 1 |
| Ciccolini, J; Mercier, C | 1 |
| Schellens, JH | 1 |
| Boumba, VA; Fountzilas, G; Golfinopoulos, V; Marselos, M; Nikiforidis, L; Nikolaidou, M; Pappas, P; Pavlidis, N; Pentheroudakis, G; Siarabi, O; Tzamakou, E; Vougiouklakis, T | 1 |
| Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A | 1 |
| Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS | 1 |
| Alexandre, J; Bertheault-Cvitkovic, F; Cvitkovic, E; Faivre, S; Goldwasser, F; Hilgers, W; Kahatt, C; Lokiec, F; MacDonald, JR; Raymond, E; Shah, A; Shibata, S; Weems, G | 1 |
| Baehring, JM; Fulbright, RK | 1 |
| Arya, N; Chu, QS; Curtright, J; de Bono, J; Fleming, RA; Ho, PT; Koch, KM; Pandite, L; Rowinsky, EK; Schwartz, G; Smith, DA; Versola, MJ | 1 |
| Guzin, G; Yucel, I | 1 |
| Bozionelou, V; Georgoulias, V; Gioulbasanis, I; Kalykaki, A; Karabeazis, A; Karampeazis, A; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B | 1 |
| Baldwin, J; Basche, M; Britten, CD; Camidge, DR; Darstein, C; Finn, RS; Gail Eckhardt, S; Gore, L; Holden, SN; Leong, S; Musib, L; O'Bryant, CL; Thornton, D | 1 |
| Arends, J; Drevs, J; Frost, A; Häring, B; Hennig, J; Medinger, M; Mross, K; Steinbild, S; Strecker, R; Unger, C | 1 |
| Boyle, F; Burris, HA; Byrne, J; Chan, S; Crown, JP; Jones, S; Koehler, M; Newstat, BO; Oliva, C; Parikh, R; Preston, A | 1 |
| Ranieri, G; Ribatti, D; Roccaro, AM; Vacca, A | 1 |
| Beard, M; Cohen, SJ; Engstrom, PF; Langer, CJ; Lewis, NL; McLaughlin, S; Meropol, NJ; Weiner, LM | 1 |
| Brell, JM; Cooney, MM; Dowlati, A; Egorin, MJ; Gibbons, J; Hoppel, CL; Ingalls, ST; Ivy, SP; Krishnamurthi, SS; Li, X; Overmoyer, BA; Remick, SC; Schluchter, MD; Weaver, KC; Zuhowski, EG | 1 |
| Albanell, J; Beech, J; Brewster, M; Gascon, P; Jones, ET; Mellado, B; Montagut, C; Pronk, L; Saunders, MP; Valle, JW; Zugmaier, G | 1 |
| Behr, J; Berghorn, E; Budman, DR; Creaven, PJ; Gordon, RJ; Griffin, T; Lichtman, SM; Meropol, NJ; Osterwalder, B; Reigner, B | 1 |
| Allman, D; Griffin, T; Kaye, S; Mackean, M; Osterwalder, B; Planting, A; Reigner, B; Schellens, J; Twelves, C; Verweij, J | 1 |
| Allman, D; Bissett, D; Cassidy, J; Dirix, L; Griffin, T; Osterwalder, B; Reigner, B; Van Oosterom, AT | 1 |
| Ishikawa, T; Ishitsuka, H; Miwa, M; Mori, K; Nishida, M; Sawada, N; Shimma, N; Umeda, I; Ura, M | 1 |
| Banken, L; Cassidy, J; Clive, S; Goggin, T; Jodrell, D; Mulligan, T; Reigner, B; Roos, B; Schulz, R; Utoh, M; Weidekamm, E | 1 |
| González Barón, M | 1 |
| Frye, DK; Mrozek-Orlowski, ME; Sanborn, HM | 1 |
| Cassidy, J | 1 |
| Banken, L; Bush, E; Cameron, D; Cassidy, J; Goggin, T; Jodrell, D; Jones, D; O'Byrne, K; Reigner, B; Roos, B; Steward, W; Twelves, C; Weidekamm, E | 1 |
| Aherne, W; Beale, PJ; Bush, E; Crompton, T; Jones, D; Judson, IR; Reigner, B; Trigo, JM | 1 |
| Burger, HU; Burris, HA; Drengler, RL; Eckhardt, SG; Griffin, T; Kraynak, M; Moczygemba, J; Reigner, B; Rodrigues, G; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR | 1 |
| Horii, I; Ishitsuka, H; Shimma, N | 1 |
| Aoyagi, S; Fujii, H; Fukuda, M; Hasegawa, M; Hirakawa-YS Chung, K; Ikeda, T; Imamoto, H; Kameyama, M; Kinoshita, H; Kitamura, M; Kubota, T; Makuuchi, H; Manabe, T; Mizutani, K; Mori, K; Murai, M; Nagasue, N; Nakao, A; Nakashima, Y; Nishida, M; Ogawa, M; Oka, M; Onishi, Y; Ozono, S; Sasaki, H; Shimada, Y; Takasaki, K; Toi, M; Toma, H; Tono, T; Yamana, H | 1 |
| Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J | 1 |
| Lewis, NL; Meropol, NJ | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 1 |
| de Bono, JS; Twelves, CJ | 1 |
| Moiseenko, VM; Orlova, RV; Semenova, AI | 1 |
| Horii, I; Ishitsuka, H; Kato, Y; Kusuhara, H; Sugiyama, Y; Tsukamoto, Y; Ura, M | 1 |
| Lawrence, TS; McGinn, CJ | 1 |
| Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Budd, GT; Bukowski, R; Chang, DZ; Ganapathi, R; Olencki, T; Osterwalder, B; Peereboom, D | 1 |
| Wilke, H | 1 |
| Banken, L; Cassidy, J; Gardiner, J; Harper, P; Johnston, P; Monkhouse, J; Poole, C; Reigner, B; Twelves, C; Weidekamm, E | 1 |
| Hwang, JJ; Marshall, JL | 1 |
| Clinton, S; Erdal, S; Hauger, M; Kraut, E; Monk, P; Nadella, P; Otterson, GA; Shah, M; Shapiro, C; Stanek, M; Villalona-Calero, MA | 1 |
| Baselga, J; Bisset, D; Cassidy, J; Díaz-Rubio, E; Eatock, M; Evans, TR; Regueiro, P; Sastre, J; Tabemero, J | 1 |
52 review(s) available for capecitabine and Benign Neoplasms
| Article | Year |
|---|---|
Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Fluorouracil; Humans; Incidence; Neoplasms | 2022 |
Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Topics: Capecitabine; Celecoxib; Hand-Foot Syndrome; Humans; Neoplasms; Pyridoxine; Randomized Controlled Trials as Topic; Sorafenib | 2022 |
Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoplasms; Stomach Neoplasms | 2022 |
Epothilones as Natural Compounds for Novel Anticancer Drugs Development.
Topics: Antineoplastic Agents; Capecitabine; Epothilones; Humans; Neoplasms; Paclitaxel; Tubulin Modulators | 2023 |
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Hand-Foot Syndrome; Humans; Hydro-Lyases; Neoplasms; Thymidylate Synthase | 2020 |
Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Esophageal Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Male; Neoplasms; Proton Pump Inhibitors; Retrospective Studies; Stomach Neoplasms | 2020 |
[Proton pump inhibitors and cancers: A hazardous association?]
Topics: Antineoplastic Agents; Bacterial Infections; Capecitabine; Contraindications, Drug; Drug Interactions; Dysbiosis; Erlotinib Hydrochloride; Fractures, Bone; Gastrointestinal Absorption; Gastrointestinal Neoplasms; Gefitinib; Humans; Indazoles; Kidney; Neoplasms; Prognosis; Protein-Tyrosine Kinases; Proton Pump Inhibitors; Pyrimidines; Sulfonamides | 2020 |
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.
Topics: Antimetabolites, Antineoplastic; Austria; Capecitabine; Consensus; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetic Testing; Genotype; Germany; Humans; Male; Mutation; Neoplasms; Phenotype; Practice Guidelines as Topic; Switzerland; Tegafur | 2020 |
Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Humans; Neoplasms | 2021 |
Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis.
Topics: Capecitabine; Cardiotoxicity; Fluorouracil; Humans; Neoplasms; Risk Factors | 2021 |
Cardio-oncology: Capecitabine Can Sometimes be Heatbreaking Capecitabine-Induced Takotsubo Cardiomyopathy Case Report and Literature Review.
Topics: Capecitabine; Humans; Incidence; Neoplasms; Takotsubo Cardiomyopathy | 2021 |
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; France; Humans; Neoplasms; Phenotype; Practice Guidelines as Topic; Pyrimidines; Uracil | 2018 |
Fluoropyrimidine-induced cardiotoxicity.
Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Humans; Neoplasms; Pyrimidines; Pyrrolidines; Quinazolines; Thiophenes; Thymine; Trifluridine; Uracil; Uridine | 2018 |
5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration.
Topics: Acetates; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Patient Safety; Risk Assessment; Severity of Illness Index; Survival Analysis; Uridine | 2018 |
Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
Topics: Acetates; Aged; Antidotes; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Humans; Neoplasms; Uridine | 2020 |
[Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Topics: Antineoplastic Agents; Biomarkers; Breath Tests; Capecitabine; Comorbidity; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Mutation; Neoplasms; Polymorphism, Single Nucleotide; RNA, Messenger; Uracil | 2012 |
Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Heart Diseases; Humans; Neoplasms; Quinazolines; Retrospective Studies; Thiophenes | 2013 |
Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics.
Topics: Antineoplastic Agents; Body Composition; Body Mass Index; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Niacinamide; Nutritional Status; Nutritional Support; Phenylurea Compounds; Sorafenib | 2013 |
Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Camptothecin; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Neoplasms; Organoplatinum Compounds; Tegafur | 2015 |
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gastrointestinal Diseases; Genetic Predisposition to Disease; Hematologic Diseases; Humans; Multivariate Analysis; Neoplasms; Odds Ratio; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Severity of Illness Index; Tegafur | 2015 |
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.
Topics: Acetates; Animals; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Drug Approval; Drug Evaluation, Preclinical; Fluorouracil; Humans; Neoplasms; Prescription Drug Overuse; Research Design; Treatment Outcome; United States; United States Food and Drug Administration; Uridine | 2016 |
The role of pharmacogenetics in capecitabine efficacy and toxicity.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carboxylesterase; Cytidine Deaminase; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Genome-Wide Association Study; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Thymidine Phosphorylase | 2016 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome | 2009 |
Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Treatment Outcome | 2008 |
Capecitabine: have we got the dose right?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diet; Dose-Response Relationship, Drug; Fluorouracil; Humans; Maximum Tolerated Dose; Neoplasms; Pharmacogenetics; Prodrugs; Treatment Outcome | 2009 |
Safety of capecitabine: a review.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Comorbidity; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Kidney Diseases; Liver Diseases; Male; Multicenter Studies as Topic; Neoplasms; Paresthesia; Randomized Controlled Trials as Topic; Retrospective Studies; Vulnerable Populations | 2010 |
[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
Topics: Antineoplastic Agents; Capecitabine; Cytarabine; Deoxycytidine; Docetaxel; Doxorubicin; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Neoplasms; Peripheral Nervous System; Quality of Life; Severity of Illness Index; Skin; Syndrome; Taxoids | 2011 |
Pulmonary toxicity with oxaliplatin and capecitabine/5-Fluorouracil chemotherapy: a case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Deoxycytidine; Drug Administration Schedule; Dyspnea; Fluorouracil; Humans; Lung; Lung Diseases, Interstitial; Lung Volume Measurements; Male; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pulmonary Fibrosis; Tomography, X-Ray Computed | 2011 |
Tumor endothelial markers as a target in cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Cell Adhesion Molecules; Deoxycytidine; Endothelial Cells; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Neoplasms; Neoplastic Stem Cells; Receptors, Growth Factor; Thymidine Phosphorylase | 2012 |
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Discovery; Fluorouracil; Genetic Variation; Humans; Mercaptopurine; Methyltransferases; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Precision Medicine | 2013 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Pyridines; Tegafur; Treatment Outcome; Uracil | 2002 |
Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience.
Topics: Animals; Area Under Curve; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Models, Biological; Neoplasms; Technology, Pharmaceutical; Tissue Distribution | 2003 |
[Use of xeloda (capecitabine) in the treatment of cancer patients (review)].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Neoplasms; Treatment Outcome | 2003 |
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Neoplasms; Pyrimidines; Radiation-Sensitizing Agents | 2004 |
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Pyrimidinones; Tegafur; Uracil | 2004 |
Thymidylate synthase: a critical target in cancer therapy?
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Proliferation; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Neoplasms; Oxonic Acid; Prodrugs; RNA, Messenger; Tegafur; Thymidylate Synthase | 2004 |
Capecitabine: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs | 2005 |
Neurological complications of cancer chemotherapy.
Topics: Antineoplastic Agents; Capecitabine; Central Nervous System; Deoxycytidine; Fluorouracil; Humans; Magnetic Resonance Imaging; Neoplasms; Neuroprotective Agents; Peripheral Nervous System; Peripheral Nervous System Diseases; Vitamin E | 2006 |
[Capecitabine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Neoplasms; Survival Rate | 2006 |
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms; Polymorphism, Genetic | 2006 |
Capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs | 2007 |
Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Immunoassay; Medical Oncology; Neoplasms; Pharmacogenetics | 2007 |
Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Neovascularization, Pathologic; Patents as Topic; Radiotherapy; Regional Blood Flow; Thymidine Phosphorylase; Up-Regulation | 2006 |
[Oral fluoropyrimidines in oncology].
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Recurrence, Local; Neoplasms; Tegafur; Time Factors; Uracil | 1998 |
Capecitabine: nursing implications of a new oral chemotherapeutic agent.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Nursing Care; Oncology Nursing; Patient Education as Topic | 1999 |
Potential of Xeloda in colorectal cancer and other solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasms | 1999 |
[Discovery and development of novel anticancer drug capecitabine].
Topics: Animals; Antineoplastic Agents; Biological Availability; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; Drug Administration Schedule; Drug Design; Fluorouracil; Humans; Liver; Mice; Neoplasms; Taxoids; Thymidine Phosphorylase; Up-Regulation | 1999 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pyridines; Stomach Neoplasms; Tegafur; Uracil | 2000 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasms; Tegafur; Temozolomide; Uracil | 2000 |
The oral fluorinated pyrimidines.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Biotransformation; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Neoplasms; Oxidoreductases; Prodrugs; Tegafur; Uracil | 2001 |
Recent advances in the use of radiosensitizing nucleosides.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents | 2001 |
Capecitabine: fulfilling the promise of oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms; Prodrugs | 2002 |
80 trial(s) available for capecitabine and Benign Neoplasms
| Article | Year |
|---|---|
Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial.
Topics: Antimetabolites, Antineoplastic; Biological Availability; Capecitabine; Carbonated Beverages; Cross-Over Studies; Drug Interactions; Drug Monitoring; Esomeprazole; Female; Humans; Male; Middle Aged; Neoplasms; Netherlands; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2022 |
Phase I pharmacological study of continuous chronomodulated capecitabine treatment.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Circadian Rhythm; Dihydrouracil Dehydrogenase (NADP); Drug Chronotherapy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Thymidylate Synthase; Uridine Triphosphate | 2020 |
A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Topics: Activities of Daily Living; Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Capecitabine; Double-Blind Method; Doxorubicin; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pilot Projects; Polyethylene Glycols; Pyridoxine; Quality of Life; Treatment Outcome; Vitamin B Complex | 2021 |
Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Biological Variation, Population; Capecitabine; Computer Simulation; Datasets as Topic; Dose-Response Relationship, Drug; Drug Dosage Calculations; Hand-Foot Syndrome; Humans; Leukocytes, Mononuclear; Markov Chains; Models, Biological; Neoplasms; Primary Cell Culture; Prodrugs; Uridine Triphosphate | 2021 |
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Capecitabine; Chi-Square Distribution; Dihydrouracil Dehydrogenase (NADP); Double-Blind Method; Drug Administration Schedule; Female; Folic Acid; Genetic Predisposition to Disease; Genome-Wide Association Study; Hand-Foot Syndrome; Humans; Incidence; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Logistic Models; Male; Membrane Proteins; Microfilament Proteins; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pyridoxine; Risk Assessment; Risk Factors; Severity of Illness Index; Singapore; Time Factors; Treatment Outcome | 2017 |
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Prognosis; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Tissue Distribution | 2019 |
Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Female; Follow-Up Studies; Genotype; Heterozygote; Humans; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide; Practice Guidelines as Topic; Prognosis; Retrospective Studies; Survival Rate | 2019 |
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2013 |
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Everolimus; Female; Fluorouracil; Humans; Immunosuppressive Agents; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neuropilin-1; Neuropilin-2; Organoplatinum Compounds; Oxaliplatin; RNA, Messenger; Sirolimus; Vascular Endothelial Growth Factor A | 2014 |
Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Cohort Studies; Deoxycytidine; Embolization, Therapeutic; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Microspheres; Middle Aged; Neoplasms; Prospective Studies; Yttrium Radioisotopes | 2014 |
Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drugs, Chinese Herbal; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms | 2014 |
Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Nitriles; Quinolines | 2014 |
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
Topics: Aged; Amyloid Precursor Protein Secretases; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs | 2015 |
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Pilot Projects; Piperazines; Placebos; Protein Kinase Inhibitors; Purines; Pyrroles; Sildenafil Citrate; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyuridine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs | 2015 |
Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Fluorouracil; Humans; Male; Neoplasms; Tandem Mass Spectrometry; Therapeutic Equivalency | 2015 |
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.
Topics: Activation, Metabolic; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Esophageal Neoplasms; Fatigue; Female; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Prodrugs; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation; Young Adult | 2015 |
A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Capecitabine; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Male; Middle Aged; Neoplasms; Resorcinols | 2015 |
A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Cross-Over Studies; Delayed-Action Preparations; Drug Liberation; Drugs, Investigational; Humans; Neoplasms; Young Adult | 2016 |
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; DNA Adducts; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2009 |
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2009 |
Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.
Topics: Absorption; Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Tablets; Therapeutic Equivalency | 2008 |
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazoles; Quinazolines; Risk; Sulfonamides | 2008 |
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Prognosis; Tissue Distribution; Treatment Outcome | 2009 |
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression; Humans; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Oligodeoxyribonucleotides; Organoplatinum Compounds; Oxaliplatin; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2009 |
A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2010 |
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyridazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult | 2010 |
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Capecitabine; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms; Neovascularization, Physiologic; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Pyrimidines; Skin | 2010 |
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Vomiting; Young Adult | 2010 |
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Cell Cycle Proteins; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Administration Schedule; Europe; Female; Fluorouracil; Granulation Tissue; Humans; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sirolimus; Skin; Thymidine Phosphorylase; Thymidylate Synthase; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2012 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind Method; Drug Combinations; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Keratolytic Agents; Lactic Acid; Male; Middle Aged; Neoplasms; Syndrome; Urea | 2010 |
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Organoplatinum Compounds; Vomiting | 2011 |
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids | 2011 |
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Young Adult | 2012 |
Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2012 |
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2012 |
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Taxoids; Treatment Outcome | 2012 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Pyridines; Tegafur; Treatment Outcome; Uracil | 2002 |
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2003 |
Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Erythrocyte Indices; Erythrocytes; Female; Fluorouracil; Folic Acid; Hematinics; Homocysteine; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Retrospective Studies; Thymidylate Synthase; Vitamin B 12 | 2003 |
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2004 |
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Mouth Mucosa; Nausea; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Treatment Outcome; Vomiting | 2004 |
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Histone Deacetylase Inhibitors; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Phenylenediamines; Stomatitis; Thrombocytopenia; Treatment Outcome | 2004 |
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2005 |
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mucous Membrane; Neoplasms; Taxoids | 2005 |
A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2005 |
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Taxoids; Treatment Outcome; Vomiting | 2005 |
Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Topotecan; Treatment Outcome | 2005 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Humans; Irinotecan; Middle Aged; Models, Biological; Molecular Structure; Neoplasm Metastasis; Neoplasms; Prodrugs; Sesquiterpenes | 2005 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors | 2006 |
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Protein Prenylation; Quinolones | 2006 |
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Treatment Outcome | 2007 |
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Carboxylesterase; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2007 |
Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administration Routes; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Prodrugs | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Temozolomide; Thalidomide; Treatment Outcome | 2007 |
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Sesquiterpenes; Treatment Outcome | 2007 |
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Child, Preschool; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines | 2007 |
A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2007 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Mitomycin; Nausea; Neoplasms; Skin Diseases; Taxoids; Treatment Outcome; Vomiting | 2007 |
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Monocytes; Neoplasms; Phosphorylation; Protein Kinase C; Protein Kinase C beta | 2008 |
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Treatment Outcome | 2007 |
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrazines | 2008 |
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2009 |
A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms | 2008 |
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms | 1998 |
A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Treatment Outcome | 1998 |
Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aluminum Hydroxide; Antacids; Antineoplastic Agents; Biotransformation; Capecitabine; Cross-Over Studies; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Half-Life; Humans; Magnesium Hydroxide; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms | 1999 |
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Topics: Analysis of Variance; Antineoplastic Agents; Area Under Curve; Biotransformation; Body Surface Area; Capecitabine; Confidence Intervals; Creatinine; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Half-Life; Humans; Male; Metabolic Clearance Rate; Neoplasms; Regression Analysis; Sex Characteristics; Tablets; Therapeutic Equivalency | 1999 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bilirubin; Capecitabine; Cohort Studies; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 1999 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; Capecitabine; Carboxylic Ester Hydrolases; Deamination; Deoxycytidine; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Fever; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Paronychia; Prodrugs; Remission Induction; Taxoids; Treatment Outcome | 2000 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Stomatitis; Treatment Outcome | 2002 |
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromatography, Liquid; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Subcutaneous; Interferon-alpha; Kidney Neoplasms; Male; Mass Spectrometry; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Peripheral Nervous System Diseases | 2001 |
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Deoxycytidine; Fluorouracil; Half-Life; Humans; Kidney; Metabolic Clearance Rate; Neoplasms; Regression Analysis; Safety | 2002 |
Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Thymidine Phosphorylase | 2002 |
Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2002 |
104 other study(ies) available for capecitabine and Benign Neoplasms
| Article | Year |
|---|---|
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.
Topics: Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotyping Techniques; Humans; Neoplasms; Patient Selection; Polymorphism, Single Nucleotide | 2022 |
Topics: Antimetabolites, Antineoplastic; Capecitabine; Female; Fluorouracil; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Restriction Fragment Length | 2022 |
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Cardiotoxicity; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Young Adult | 2022 |
Renal impairment and DPD testing: Watch out for false-positive results!
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms; Renal Insufficiency; Uracil | 2022 |
Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours.
Topics: Antibodies, Bispecific; Antineoplastic Agents; Capecitabine; Humans; Neoplasms; T-Lymphocytes | 2022 |
Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Treatment Outcome | 2022 |
Updated Labeling for Capecitabine, a 25-Year-Old Cancer Drug.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Neoplasms | 2023 |
Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Neoplasms | 2023 |
Physiologically Based Pharmacokinetic Modeling for Prediction of 5-FU Pharmacokinetics in Cancer Patients with Hepatic Impairment After 5-FU and Capecitabine Administration.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms | 2023 |
Survival of Patients With Cancer With
Topics: Alleles; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Matched-Pair Analysis; Neoplasms; Prospective Studies; Retrospective Studies | 2023 |
Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer.
Topics: Aged; Aneurysm; Aortic Dissection; Arteries; Capecitabine; Cohort Studies; Female; Humans; Male; Middle Aged; Neoplasms; Tyrosine Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2023 |
Prevalence of the DPYD variant (Y186C) in Brazilian individuals of African ancestry.
Topics: Antimetabolites, Antineoplastic; Black People; Brazil; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Healthy Volunteers; Humans; Male; Mutation; Neoplasms; Prevalence | 2019 |
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Floxuridine; Gastrectomy; Humans; Male; Middle Aged; Neoplasms; Pharmacogenomic Variants; Prodrugs | 2019 |
Improvement in adherence to Capecitabine and Lapatinib by way of a therapeutic education program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Lapatinib; Male; Medication Adherence; Middle Aged; Neoplasms; Prospective Studies | 2020 |
Hierarchical Responsive Nanoplatform with Two-Photon Aggregation-Induced Emission Imaging for Efficient Cancer Theranostics.
Topics: Animals; Capecitabine; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Drug Liberation; Humans; Hydrogen-Ion Concentration; Mice; Molecular Imaging; Nanoparticles; Neoplasms; Photons; Polymers; Reactive Oxygen Species; Theranostic Nanomedicine; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Chromatography, High Pressure Liquid; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Spectrophotometry, Ultraviolet; Uracil | 2020 |
DPD status and fluoropyrimidines-based treatment: high activity matters too.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2020 |
The generalized inference on the ratio of mean differences for fraction retention noninferiority hypothesis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Computer Simulation; Data Interpretation, Statistical; Drug Development; Equivalence Trials as Topic; Humans; Models, Statistical; Neoplasms; Research Design; Treatment Outcome | 2020 |
Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cadherins; Capecitabine; Cell Line; Female; Genetic Predisposition to Disease; Hand-Foot Syndrome; Haplotypes; Humans; Keratinocytes; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Risk | 2021 |
Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Male; Markov Chains; Middle Aged; Neoplasms; Patient Reported Outcome Measures; Prognosis; Prospective Studies | 2020 |
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Capecitabine; Carboplatin; Dexamethasone; Etoposide; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Oxaliplatin; Paclitaxel; Pre-Exposure Prophylaxis; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2020 |
Genome-Guided Reassurance of Drug Safety in Cancer Therapy: The Paradigm of Fluorouracil.
Topics: Capecitabine; Fluorouracil; Genetic Testing; Humans; Neoplasms; Pharmaceutical Preparations | 2020 |
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.
Topics: Aged; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genetic Variation; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Risk Factors; Treatment Outcome | 2021 |
Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
Topics: Aged; Antimetabolites, Antineoplastic; Canada; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Heterozygote; Humans; Male; Medical Oncology; Middle Aged; Neoplasms; Pharmacogenomic Testing; Pharmacogenomic Variants; Practice Guidelines as Topic; Precision Medicine; Retrospective Studies | 2021 |
Association of Pharmacogenetics With Adverse Events of Fluorouracil/Capecitabine in Patients With Cancer.
Topics: Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Pharmacogenetics | 2021 |
Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; beta-Alanine; Capecitabine; Female; Fluorouracil; Humans; Male; Middle Aged; Muscle, Skeletal; Neoplasms; Prodrugs; Sex Factors; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Capecitabine induced Steven-Johnson syndrome: A rare case report.
Topics: Aged; Antineoplastic Agents; Capecitabine; Fluorouracil; Humans; Male; Neoplasms; Stevens-Johnson Syndrome | 2022 |
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genotype; Hospitalization; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasms; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Predictive Value of Tests; Prospective Studies; Thymidylate Synthase; Uracil; Young Adult | 2017 |
Conflict of Interest and the CREATE-X Trial in the New England Journal of Medicine.
Topics: Authorship; Biomedical Research; Capecitabine; Conflict of Interest; Disclosure; Drug Industry; Editorial Policies; Ethics, Research; Humans; Japan; Neoplasms; New England; Periodicals as Topic; Publishing; Research Personnel; Scientific Misconduct | 2018 |
Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine.
Topics: Administration, Topical; Aged; Angiolymphoid Hyperplasia with Eosinophilia; Antimetabolites, Antineoplastic; Capecitabine; Cohort Studies; Female; Humans; Male; Middle Aged; Neoplasms; Paronychia; Prognosis; Retrospective Studies; Timolol; Treatment Outcome | 2018 |
Computer tomography-based body surface area evaluation for drug dosage: Quantitative radiology versus anthropomorphic evaluation.
Topics: Adult; Aged; Aged, 80 and over; Anthropometry; Antineoplastic Agents; Body Surface Area; Capecitabine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Reproducibility of Results; Retrospective Studies; Software; Tomography, X-Ray Computed | 2018 |
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; China; Female; Fluorouracil; Heart Diseases; Humans; Incidence; Male; Middle Aged; Neoplasms; Prospective Studies; Risk Assessment; Young Adult | 2018 |
Analysis of data on capecitabine-related adverse drug reactions from the Korean adverse event reporting system database.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Capecitabine; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasms; Republic of Korea | 2018 |
Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity.
Topics: Black People; Capecitabine; Carboplatin; Cell Line; Cisplatin; Gene Expression Regulation, Neoplastic; Genetic Variation; Genome-Wide Association Study; Genome, Human; Humans; Molecular Sequence Annotation; Neoplasms; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; White People | 2019 |
Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients.
Topics: Adult; Aged; Amidohydrolases; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Phenotype; Thymine | 2018 |
Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antioxidants; Capecitabine; Carotenoids; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Skin; Sorafenib; Sunitinib | 2018 |
Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Humans; Leukocytes, Mononuclear; Limit of Detection; Lymphocytes; Monocytes; Neoplasms; Sensitivity and Specificity; Thymidine; Thymidine Phosphorylase; Thymine | 2018 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Frequency; Heterozygote; Homozygote; Humans; Male; Middle Aged; Neoplasms; Netherlands; Pharmacogenomic Variants; Prospective Studies; Time Factors; Treatment Outcome | 2018 |
Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotoxicity; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Fluorouracil; Follow-Up Studies; Heart Diseases; Humans; Incidence; Neoplasms; Prognosis; United States | 2019 |
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Clinical Trials as Topic; Databases, Factual; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Genetic Predisposition to Disease; Genotype; Hematologic Diseases; Humans; Inactivation, Metabolic; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Young Adult | 2018 |
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Matched-Pair Analysis; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide; Retrospective Studies | 2019 |
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Costs and Cost Analysis; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genetic Testing; Genotype; Humans; Neoplasms; Polymorphism, Genetic; Precision Medicine; Prognosis; Prospective Studies | 2019 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how?
Topics: Capecitabine; Dihydrouracil Dehydrogenase (NADP); Genotype; Humans; Neoplasms; Prospective Studies | 2019 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors' reply.
Topics: Capecitabine; Dihydrouracil Dehydrogenase (NADP); Genotype; Humans; Neoplasms; Prospective Studies | 2019 |
Pharmacogenomic potential in advanced cancer patients.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Drug Prescriptions; Female; Humans; Male; Middle Aged; Neoplasms; Ondansetron; Pharmacogenomic Testing; Pharmacogenomic Variants; Precision Medicine; Prospective Studies; Retrospective Studies; Sertraline | 2019 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Prospective Studies; Vomiting; Young Adult | 2013 |
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2014 |
Using continuous data on tumour measurements to improve inference in phase II cancer studies.
Topics: Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II as Topic; Computer Simulation; Data Interpretation, Statistical; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Neoplasms | 2013 |
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbamates; Carboxylesterase; Cell Line, Tumor; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Hydrolysis; Mice; Mice, Inbred BALB C; Neoplasms; Quinazolines; Thymidine Phosphorylase | 2013 |
[Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Arginine; Butyrates; Capecitabine; Deoxycytidine; Female; Fluorouracil; Glutamine; Hand-Foot Syndrome; Humans; Hydroxy Acids; Male; Middle Aged; Neoplasms | 2013 |
Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Capecitabine; Cell Cycle Checkpoints; Cell Line, Tumor; Citric Acid Cycle; Cytotoxins; Deoxycytidine; Fluorouracil; Glutamine; Humans; Mutation; Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2015 |
Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cross-Sectional Studies; Deoxycytidine; Female; Fluorouracil; Humans; Malaysia; Male; Medication Adherence; Middle Aged; Nausea; Neoplasms; Patient Satisfaction; Sex Factors; Vomiting | 2014 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Chromatography, Liquid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxyuracil Nucleotides; Deoxyuridine; Fluorouracil; Humans; Leukocytes, Mononuclear; Neoplasms; Tandem Mass Spectrometry; Uridine Triphosphate | 2016 |
Detection of capecitabine (Xeloda®) on the skin surface after oral administration.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Female; Fluorine; Humans; Male; Middle Aged; Neoplasms; Skin; Spectrum Analysis; Sweat | 2016 |
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions.
Topics: Antineoplastic Agents; Capecitabine; Docetaxel; Drug Administration Schedule; Humans; Neoplasms; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Pharmacovigilance; Phenylurea Compounds; Retrospective Studies; Sorafenib; Taxoids; Treatment Outcome | 2016 |
Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
Topics: Antineoplastic Agents; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genotype; Humans; Male; Neoplasms; Pharmacogenomic Testing; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Prospective Studies | 2016 |
Hemoglobin Value Is the Most Important Factor in the Development of Hand-Foot Syndrome under the Capecitabine Regimen.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Female; Follow-Up Studies; Hand-Foot Syndrome; Hemoglobins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Odds Ratio; Proportional Hazards Models; Risk Factors | 2017 |
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); DNA, Complementary; Female; Fluorouracil; Gene Expression; Genetic Variation; Genotype; Haplotypes; Humans; Introns; Male; Middle Aged; Mutation; Neoplasms; Precision Medicine; Retrospective Studies | 2016 |
Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
Topics: Acetates; Antimetabolites, Antineoplastic; Capecitabine; Drug Overdose; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Uridine | 2017 |
Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents:
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinofuranosyluracil; Capecitabine; Dideoxynucleosides; Female; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2016 |
Adherence with capecitabine: A population-based analysis based on prescription refill data.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Drug Prescriptions; Female; Humans; Male; Medication Adherence; Neoplasms; Software | 2017 |
Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Amplification; HEK293 Cells; Humans; Male; Middle Aged; Models, Molecular; Mutation; Mutation, Missense; Neoplasms; Pharmacogenomic Variants; RNA Splicing; Sequence Deletion | 2017 |
Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Denmark; Drug Combinations; Drug Substitution; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Netherlands; Oxonic Acid; Retrospective Studies; Tegafur; Treatment Outcome; Western World | 2017 |
Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carboxylic Ester Hydrolases; Cohort Studies; Forecasting; Genetic Variation; Humans; Middle Aged; Neoplasms; Prodrugs; Severity of Illness Index | 2017 |
Adherence and safety study in patients on treatment with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Cohort Studies; Female; Humans; Male; Middle Aged; Neoplasms; Patient Compliance; Prospective Studies | 2017 |
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Frequency; Genetic Variation; Haplotypes; Humans; Introns; Male; Middle Aged; Mutation; Neoplasms; Polymorphism, Genetic; Sequence Analysis, DNA; Severity of Illness Index; Stomach Neoplasms; White People | 2009 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Palliative Care; Pemetrexed; Prospective Studies; Radiation Tolerance; Radiotherapy Dosage; Young Adult | 2010 |
The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetic Variation; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies | 2010 |
Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Neoplasms; Risk Factors; Stomach Neoplasms | 2010 |
Phase I studies of drug combinations.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Evidence-Based Medicine; Fluorouracil; Humans; Intracellular Signaling Peptides and Proteins; Maximum Tolerated Dose; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
[Therapeutic adherence to oral cancer therapy and interdisciplinary management].
Topics: Adenocarcinoma; Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Cecal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interdisciplinary Communication; Male; Medication Adherence; Neoplasms; Outpatients; Patient-Centered Care; Pharmacists; Physician's Role; Pilot Projects; Piperazines; Prospective Studies; Pyrimidines; Switzerland; Time Factors; Treatment Outcome | 2011 |
Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Prodrugs; Pyrimidines; Treatment Outcome; Uridine Phosphorylase | 2011 |
Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Imatinib Mesylate; Neoplasms; Netherlands; Pharmacies; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
Clinical and electrocardiography changes in patients treated with capecitabine.
Topics: Capecitabine; Cardiovascular Diseases; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Humans; Long QT Syndrome; Male; Middle Aged; Neoplasms; Treatment Outcome | 2011 |
Mobile health for drug dose optimisation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Blood Glucose Self-Monitoring; Capecitabine; Deoxycytidine; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Computer-Assisted; Female; Fluorouracil; Humans; Hypoglycemic Agents; Insulin; Neoplasms; Telemedicine; Treatment Outcome | 2011 |
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Peripheral Nervous System Diseases; Proportional Hazards Models; Risk Factors; Severity of Illness Index; Time Factors; Tubulin Modulators; Young Adult | 2012 |
A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Creatinine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Middle Aged; Neoplasms; Renal Dialysis; Renal Insufficiency; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |
[Predicting drug efficacy-fluorinated pyrimidines (fluorouracil, S-1 and capecitabine)].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Neoplasms; Oxonic Acid; Prognosis; Tegafur | 2012 |
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Female; Fluorouracil; Genetic Testing; Genotype; Humans; Male; Middle Aged; Neoplasms; Risk Assessment; Tegafur | 2012 |
Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Floxuridine; Fluorouracil; Mice; Mice, Nude; Neoplasms; Nucleoside-Phosphate Kinase; Orotate Phosphoribosyltransferase; Ribonucleotide Reductases; RNA, Messenger; Thymidine Kinase; Thymidine Phosphorylase; Thymidylate Synthase; Uridine Kinase; Uridine Phosphorylase | 2013 |
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Cytokines; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Glioblastoma; Humans; Interferon-gamma; Liver; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Oxidoreductases; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Thymidine Phosphorylase; Time Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Capecitabine in colorectal, breast, and other solid tumors: novel therapeutic approaches. Selected abstracts from ASCO 2003.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs | 2003 |
Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies | 2004 |
Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers.
Topics: Animals; Capecitabine; Deoxycytidine; Fluorine Radioisotopes; Fluorouracil; Humans; Isotope Labeling; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2004 |
The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Mutation; Neoplasms; S Phase; Time Factors; Treatment Outcome | 2005 |
Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients.
Topics: Atmospheric Pressure; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Deoxyuridine; Drug Stability; Fluorouracil; Humans; Mass Spectrometry; Neoplasms; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer.
Topics: Adult; Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Synergism; Factor VII; Fluorouracil; Half-Life; Humans; Middle Aged; Neoplasms; Prothrombin Time; Vitamin K 1; Warfarin | 2005 |
Albumin-bound nanoparticle paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Nanostructures; Nanotechnology; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Prodrugs | 2005 |
A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Topics: Adult; Aged; Anemia, Hypochromic; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Neutropenia; Platelet Count; Polyethylene Glycols; Treatment Outcome | 2005 |
Timing of significant adverse events is essential information during early development of new drugs.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Maximum Tolerated Dose; Neoplasms | 2006 |
A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Blood Coagulation Disorders; Capecitabine; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Polypharmacy; Retrospective Studies; Warfarin | 2006 |
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Deoxycytidine; Enzyme Activators; Enzyme Inhibitors; Flow Cytometry; Fluorouracil; Follow-Up Studies; Humans; Indoles; Leukocytes, Mononuclear; Monocytes; Neoplasms; Protein Kinase C; Protein Kinase C beta; Reproducibility of Results; Sensitivity and Specificity; Signal Transduction; Structure-Activity Relationship; Treatment Outcome | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Cohort Studies; Data Interpretation, Statistical; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gastrointestinal Tract; Humans; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design | 2006 |
Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.
Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Edema; Capecitabine; Dementia, Vascular; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Energy Metabolism; Female; Fluorouracil; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Infusions, Intravenous; Injections, Spinal; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neoplasms; Nerve Fibers, Myelinated; Neurologic Examination; Registries; Remission, Spontaneous; Stroke; Tegafur | 2008 |
Topical henna for capecitabine induced hand-foot syndrome.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Naphthoquinones; Neoplasms; Paresthesia; Severity of Illness Index; Syndrome; Treatment Outcome | 2008 |
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diarrhea; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2008 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Liver; Male; Mice; Neoplasms; Thymidine Phosphorylase | 1998 |
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Feces; Female; Fluorouracil; Gas Chromatography-Mass Spectrometry; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasms; Time Factors | 1999 |
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Topics: Animals; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Japan; Male; Neoplasms; Oxidoreductases; Thymidine Phosphorylase; Transplantation, Heterologous | 2000 |
[The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Neoplasms; Survival Analysis; Treatment Outcome | 2001 |
A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Blood Proteins; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Kinetics; Models, Biological; Neoplasms; Prodrugs; Protein Binding; Regional Blood Flow; Reproducibility of Results; Tissue Distribution | 2001 |
Future treatment options with capecitabine in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Taxoids | 2002 |